Compare American Electric Power Company Inc (AEP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Electric Power Company Inc vs State Street SPDR S&P Biotech ETF — how do they compare? American Electric Power Company Inc trades at $124.14 (market cap $67.28B), while State Street SPDR S&P Biotech ETF trades at $158.93. The key difference: American Electric Power Company Inc pays a 3.07% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, American Electric Power Company Inc nearer its low. Which is the better fit depends on your goals.
| AEP | XBI | |
|---|---|---|
Market Cap | $67.28B | — |
Sector | Utilities | Broad Market / Factor |
52-Week High | $138.69 | $164.28 |
52-Week Low | $106.44 | $86.92 |
Enterprise Value | $120.17B | — |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Electric Power (AEP) trades at $123.89, up 0.85% today, with a bearish technical signal but strong analyst support. Recent Q2 2026 earnings missed estimates at $1.36 EPS versus $1.48 expected, though revenue grew 7% year-over-year. The company raised full-year 2026 operating EPS guidance to $6.25–$6.55, citing robust demand from data centers and a $78 billion capital plan. Valuation metrics include a P/E of 21.42 and P/B of 2.1, with a consensus price target of $140.89 implying 14% upside.
AEP's outlook is supported by contracted load growth and infrastructure investments, but risks include execution of its capital plan and interest expense pressures. The stock offers a dividend yield with an upcoming $0.95 payment. Analyst consensus is strongly bullish with 61% buy ratings, though technical indicators suggest near-term caution. Long-term growth targets of 7–9% annually provide a solid foundation for patient investors.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
